Properties (61)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
joint_venture_with_Biogen
|
| gptkbp:advertising |
competitive pricing
patient-centric approach strategic collaborations |
| gptkbp:awards |
various industry recognitions
|
| gptkbp:clinicalTrials |
diabetes
ongoing oncology autoimmune diseases inflammatory diseases Phase I trials ongoing Phase II trials ongoing Phase III trials ongoing |
| gptkbp:collaborations |
research institutions
|
| gptkbp:community_engagement |
educational programs
awareness campaigns patient support programs healthcare_initiatives |
| gptkbp:employees |
over 1,000
|
| gptkbp:financialPerformance |
sustainable growth
increasing market share growing revenue strong investment returns |
| gptkbp:focus |
development of biosimilars
|
| gptkbp:founded |
2012
|
| gptkbp:founder |
gptkb:Samsung_Group
|
| gptkbp:future_plans |
strengthen partnerships
expand product portfolio enhance R&D capabilities increase global footprint |
| gptkbp:global_presence |
operates in multiple countries
|
| gptkbp:headquarters |
gptkb:Incheon,_South_Korea
|
| https://www.w3.org/2000/01/rdf-schema#label |
Samsung Bioepis
|
| gptkbp:industry |
biotechnology
|
| gptkbp:innovation |
focus on advanced therapies
|
| gptkbp:investmentFocus |
significant R&D funding
|
| gptkbp:market |
global
|
| gptkbp:mission |
improve patient access to biologics
enhance patient health through innovation |
| gptkbp:partnerships |
gptkb:Merck_&_Co.
academic institutions regulatory agencies healthcare_providers |
| gptkbp:primaryMission |
Biosimilar of adalimumab
|
| gptkbp:productionCompany |
state-of-the-art facilities
|
| gptkbp:productLine |
multiple biosimilars in development
|
| gptkbp:products |
biosimilars
|
| gptkbp:regulatoryCompliance |
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration adheres to global standards |
| gptkbp:research_focus |
oncology
chronic diseases immunology metabolic diseases |
| gptkbp:researchAndDevelopment |
biologics
|
| gptkbp:subsidiary |
gptkb:Samsung_Biologics
|
| gptkbp:supplyChain |
robust and efficient
|
| gptkbp:sustainability |
commitment to environmental practices
|
| gptkbp:technology |
recombinant DNA technology
|
| gptkbp:vision |
lead in biosimilars market
|